Stocks Health care SPRO
NASDAQ · Health careSpero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc. brought in $47M of revenue over the twelve months to June 30, 2026, down 3.3% from a year earlier. Net income was $7.4M, a net margin of 15.7%. At June 30, 2026 it held $50.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Spero Therapeutics, Inc.
- Net worth
- Spero Therapeutics, Inc. has a market value (market cap) of $60M at the latest share price, and shareholders' equity of $44.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $66.8M (+39.2% year on year), with net income of $8.6M. Over the 12 months to June 30, 2026: revenue $47M, net income $7.4M.
- Cash flow
- In fiscal 2025 operations used $12.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Spero Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Spero Therapeutics, Inc. does
Spero Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SPRO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $66.8M | $8.6M | $0.15 | n/a |
| 2024 | $48M | -$68.6M | -$1.27 | n/a |
| 2023 | $103.8M | $22.8M | $0.43 | n/a |
| 2022 | $53.5M | $46.4M | -$1.23 | n/a |
| 2021 | $18.3M | -$89.8M | -$2.91 | n/a |
| 2020 | $9.3M | -$78.3M | -$3.52 | -$86M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SPRO ranks in Health care
Latest SEC filings
What Spero Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 28, 2026
- August 28, 2026
- August 12, 2026
- August 12, 2026
- July 14, 2026
- June 25, 2026
- June 23, 2026
- June 22, 2026
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 96% to $258K versus the same quarter last year; diluted EPS -$0.13 versus -$0.25.
- May 13, 2026
Insider trades
What the people running Spero Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 3, 2026 | Zack DebraChief Medical Officer | Received as pay | 162,311 | - |
| June 23, 2026 | Pottage John C JrDirector | Received as pay | 10,000 | - |
| June 23, 2026 | Jackson Scott ThomasDirector | Received as pay | 10,000 | - |
| June 23, 2026 | Thomas Frank EDirector | Received as pay | 10,000 | - |
| June 23, 2026 | Vink Patrick V.J.J.Director | Received as pay | 10,000 | - |
| June 23, 2026 | Smith CynthiaDirector | Received as pay | 10,000 | - |
| June 23, 2026 | Tregoning KathleenDirector | Received as pay | 10,000 | - |
| June 23, 2026 | Deshpande MilindDirector | Received as pay | 10,000 | - |
Who owns SPRO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 60 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| GSK plc | 9,190,606 | 0 |
| Pfizer Inc | 2,362,348 | 0 |
| Vanguard Capital Management LLC | 2,036,226 | +236,346 |
| Renaissance Technologies LLC | 947,904 | -241,331 |
| Alphabet Inc. | 889,979 | 0 |
| Susquehanna International Group, Llp | 759,290 | +426,175 |
| BlackRock, Inc. | 594,404 | +161,202 |
| Geode Capital Management, LLC | 566,329 | +46,407 |
| Raymond James Financial Inc | 521,705 | new |
| Two Sigma Investments, LP | 382,814 | -502,817 |
| Arrowstreet Capital, Limited Partnership | 332,970 | new |
| Vanguard Fiduciary Trust Co | 287,648 | +23,533 |
| Dimensional Fund Advisors LP | 274,820 | +245,052 |
| Goldman Sachs Group Inc | 256,985 | new |
| State Street Corp | 214,751 | 0 |
| Jane Street Group, LLC | 158,097 | +51,752 |
| UBS Group AG | 139,680 | +136,671 |
| Bridgeway Capital Management, LLC | 114,800 | 0 |
| Northern Trust Corp | 108,274 | -12,710 |
| Point72 Asset Management, L.P. | 104,377 | +44,709 |
Insiders
10 insiders reported holding 2,503,122 shares in total, about $2.6M at the last price.
| Holder | Shares |
|---|---|
| Rajavelu EstherSee Remarks | 986,851 |
| Keutzer TimothyChief Operating Officer | 742,506 |
| Zack DebraChief Medical Officer | 162,311 |
| Deshpande MilindDirector | 101,454 |
| Thomas Frank EDirector | 85,000 |
| Tregoning KathleenDirector | 85,000 |
| Smith CynthiaDirector | 85,000 |
| Pottage John C JrDirector | 85,000 |
| Vink Patrick V.J.J.Director | 85,000 |
| Jackson Scott ThomasDirector | 85,000 |
Questions about SPRO
What does Spero Therapeutics, Inc. do?
Spero Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as SPRO. Its shares trade on NASDAQ under the ticker SPRO.
What is Spero Therapeutics, Inc.'s net worth?
Spero Therapeutics, Inc. has a market value (market cap) of $60M at the latest share price, and shareholders' equity of $44.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Spero Therapeutics, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $7.4M on revenue of $47M, a net margin of 15.7%.
How much revenue does Spero Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Spero Therapeutics, Inc. reported revenue of $47M. That is 3.3% less than a year earlier.
When did Spero Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from August 28, 2026.
When is Spero Therapeutics, Inc.'s next earnings report?
Spero Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SPRO with
Follow SPRO
Get an email when Spero Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Spero Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.